PFE·Healthcare·Pharma
Pfizer CFO Transition -2.9%: Stock Drops After CFO Exit
Can Pfizer convince Wall Street this CFO change is about continuity, not a deeper warning on execution and growth?
Pharma
PFE·Healthcare·Pharma
NVO·Healthcare·Pharma
Novo Nordisk Wegovy Hits 3M U.S. Prescriptions in 22 Weeks
Has Novo Nordisk Wegovy just delivered the prescription surge that forces Wall Street to rethink the entire obesity trade?
NVO·Healthcare·Pharma
Novo Nordisk Wegovy Faces a Warning in the Obesity Race
Can Novo Nordisk Wegovy regain momentum fast enough to challenge Eli Lilly before the next wave of obesity drugs resets…
LLY·Healthcare·Pharma
Eli Lilly Acquisition Signals Pain Drug Boom Beyond GLP-1
Can Eli Lilly’s latest deal prove the company is more than a one-theme GLP-1 growth story?
MRK·Healthcare·Pharma
Merck Protillion Collaboration Sends MRK Soaring 15%
Can the Merck Protillion Collaboration really help MRK outrun its post-Keytruda patent fears and justify Wall Street’s sudden excitement?
LLY·Healthcare·Pharma
Eli Lilly Orforglipron Powers $19.8B Surge as Risks Rise
Can Eli Lilly Orforglipron justify Lilly’s trillion-dollar valuation as GLP-1 growth accelerates and pricing pressure starts to bite?
JNJ·Healthcare·Dividend Aristocrats
Johnson & Johnson IMAAVY: $24B Revenue Surge in Focus
Can Johnson & Johnson IMAAVY and a $24 billion quarter finally convince investors that JNJ deserves a higher growth multiple?
NVO·Healthcare·Pharma
Novo Nordisk Wegovy Falls 4.5% on Pipeline Warning
Can Novo Nordisk Wegovy keep its obesity lead if Wall Street starts caring more about the next drug than today’s…
NVO·Healthcare·Pharma
Novo Nordisk Wegovy Trial Drives 4.2% Stock Surge
Can the Novo Nordisk Wegovy Trial strengthen its obesity lead just as Wall Street starts pricing in the next GLP-1…
MDT·Healthcare·Dividend Aristocrats
Medtronic Upgrade Sends Shares Up 5.1% After Q2 Beat
Is the Medtronic Upgrade the start of a bigger rerating, or just a brief earnings-fueled spike?